bioRxiv · 10.1101/2023.12.30.573733
Development of a PROTAC Targeting Chk1
Abstract
A series of Chk1 degraders were designed and synthesized. The degraders were developed through the conjugation of a promiscuous kinase binder and thalidomide. One of the degraders PROTAC-2 was able to decrease Chk1 levels in a concentration-dependent manner in A375 cells. The developed probes can be useful for the development of selective and more potent Chk1 degraders.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Chowdhury, S. R., Chuong, P., Mgbemena, V. E., Statsyuk, A. V.. 2024-01-01. Development of a PROTAC Targeting Chk1. https://doi.org/10.1101/2023.12.30.573733
Cite the original work for its findings. Save a collection to share your selection of sources.